Shorla Oncology Welcomes Rayna Sethi Herman as Chief Commercial Officer

Industry veteran brings more than three decades of leadership and experience in life sciences commercialization to lead Shorla’s continued US expansion

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Shorla Oncology (‘Shorla’), a US-Ireland specialty pharmaceutical company, has announced the appointment of Rayna Sethi Herman as Chief Commercial Officer (CCO). Rayna will play a key role in the commercial advancement of Shorla’s pipeline of specialty oncology drugs, including the growth of Nelarabine Injection which was launched in May, and the launch of Jylamvo in the US market, an oncology and autoimmune drug that the Company acquired in October.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231207999977/en/

Left to right: Sharon Cunningham, CEO, Rayna Sethi Herman, CCO, and Orlaith Ryan, CTO (Photo: Business Wire)

Rayna brings to Shorla more than 30 years of expertise in commercialization and has launched more than 20 biopharmaceutical products in her career. Most recently, she served as CCO at EVERSANA, the leading provider of commercial services to the life sciences industry. During her tenure, Rayna launched oncology and rare disease products through EVERSANA’s Complete Commercialization Program. Prior to joining EVERSANA, she built and sold Health Strategies Group, a firm that was the leading provider of market access insights for biopharma executives.

Rayna has also held roles of varying responsibility at Merck & Co. and sits on the board of advisors at Almaden Genomics.

“We are delighted to have Rayna join our team,” said Sharon Cunningham, Chief Executive Officer at Shorla Oncology. “We are at an important moment in our growth, and her leadership will be instrumental in the continued advancement of our product portfolio and strengthening of our position as an established specialty US Oncology company. We are confident that her expertise will contribute significantly to our ongoing efforts to bring differentiated and essential treatments to patients in need.”

The news comes shortly after Shorla announced that it has raised $35 million in Series B funding to accelerate the growth of its growing portfolio of oncology drugs. This year, Shorla also announced the US approval and launch of Nelarabine Injection and the acquisition and imminent launch of Jylamvo Oral Solution.

“I am thrilled to be joining Shorla Oncology as Chief Commercial Officer,” said Rayna Sethi Herman. “Having worked alongside the Shorla team at EVERSANA, I have seen firsthand their commitment to bringing therapies to market that will address drug shortages and improve the preparation and adherence of oncology medication. I am inspired by the team and the quality of their products and I look forward to leading the company’s commercialization efforts and bringing its much-needed treatments to market.”

About Shorla Oncology

Established in 2018 by Sharon Cunningham and Orlaith Ryan, Shorla Oncology is a privately held, US- and Ireland based specialty pharmaceutical company with an advanced pipeline of innovative oncology drugs for orphan and pediatric cancers. The company concentrates on indications where existing treatments are limited, in shortage, or the drug applications are inadequate for the target population. Shorla’s growing portfolio brings accessible, affordable and life-saving differentiated treatments to patients, delivering a major contribution to patient care.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231207999977/en/